Article Per Year (5 Year)
p-Index From 2021 - 2026
2.59
P-Index
This Author published in this journals
All Journal Majalah Kedokteran Bandung Global Medical and Health Communication Journal of Epidemiology and Public Health Indonesian Journal of Medicine Jurnal Respirologi Indonesia YARSI Medical Journal Jurnal Respirasi (JR) Narra J Kesmas: Jurnal Kesehatan Masyarakat Nasional (National Public Health Journal)
Reviono Reviono
Bagian Pulmonologi dan Kedokteran Respirasi Fakultas Kedokteran Universitas Sebelas Maret
Biochemistry, Genetics & Molecular Biology Dentistry Health Professions Immunology & microbiology Medicine & Pharmacology Nursing Public Health

Published : 23 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 4 Documents
Search
Journal : Narra J

 1 
Effectiveness of Zingiber officinale to reduce inflammation markers and the length of stay of patients with community-acquired pneumonia: An open-label clinical trial Reviono, Reviono; Hapsari, Brigitta DA.; Sutanto, Yusup S.; Adhiputri, Artrien; Harsini, Harsini; Suryawati, Betty; Marwoto, Marwoto; Syaikhu, Akhmad
Narra J Vol. 3 No. 1 (2023): April 2023
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narra.v3i1.142

Abstract

Examination of the interleukin 6 (IL-6) and procalcitonin levels, and neutrophil-lymphocyte ratio (NLR) might could help to diagnosis and predict the duration of therapy and prognosis of pneumonia cases. Zingiber officinale var rubrum could be used as an adjunct therapy in infectious diseases as it has anti-inflammatory activity. The aim of study was to assess the effect of Z. officinale on levels of IL-6 dan procalcitonin, NLR, and the length of hospitalization of patients with community-acquired pneumonia (CAP). An open-label clinical trial was conducted among CAP cases regardless of the etiology at Dr Moewardi Hospital and Universitas Sebelas Maret Hospital, Surakarta, Indonesia from July to September 2022. A total of 30 inpatient CAP cases were recruited and were randomly divided into two groups: (1) received Z. officinale capsule 300 mg daily for five days in addition to CAP standard therapy; and (2) received CAP standard therapy only, as control group. The data were compared using a paired Student t-test, Chi-squared test, Mann-Whitney test and Wilcoxon signed-rank test as appropriate. In Z. officinale group, the mean difference between post- and pre-treatment as follow: IL-6 level was 9.93 pg/mL, procalcitonin level -471.31 ng/mL, and NLR value -4.01. In control group, the difference was 18.94 pg/mL for IL-6, 339.39 ng/mL for procalcitonin, and 1.56 for NLR. The change of IL-6 was not statistically significant between treatment and control groups with p=0.917. The changes of procalcitonin level and NLR were significant between treatment and control group with p=0.024 and p=0.007, respectively, of which the treatment had better improvement. In addition, our data indicated that the length of stay was not statistically significant between the treatment and control groups (4.13 vs 4.47 days, p=0.361). In conclusion, Z. officinale could reduce serum inflammatory markers such as procalcitonin and NLR but it has little impact in reducing IL-16 level and the length of hospitalization of CAP patients.
Effects of secretome supplementation on interleukin-6, tumor necrosis factor-α, procalcitonin, and the length of stay in acute exacerbation COPD patients Fahlevie, Fahlevie; Apriningsih, Hendrastutik; Sutanto, Yusup S.; Reviono, Reviono; Adhiputri, Artrien; Aphridasari, Jatu; Prasetyo, Windu
Narra J Vol. 3 No. 2 (2023): August 2023
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narra.v3i2.171

Abstract

Acute exacerbation chronic obstructive pulmonary disease (AECOPD) is associated with significant poor survival. Mesenchymal stem cells (MSC) therapy has been a promising treatment for COPD; therefore, it has the potential to be an additional therapy for AECOPD. Its potential is associated with its secretome since it has anti-inflammatory and immunomodulator activities. The aim of this study was to determine the effect of the secretome as an adjuvant therapy in reducing the levels of interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), procalcitonin, and the length of stay in AECOPD patients. A clinical control trial study was conducted among 28 moderate and severe AECOPD patients who were hospitalized from January to February 2023. The control group (n=14) received standard therapy of AECOPD while the treatment group (n=14) received standard therapy plus secretome 1 ml twice daily for three days. The levels of IL-6, TNF-α, and procalcitonin were measured at admission and on the fourth day of treatment. The length of stay was calculated from the time the patient was admitted until the patient was discharged from hospital. The data were compared using a paired Student t-test, chi-squared test and Mann-Whitney test as appropriate. In the treatment group, the levels of IL-6, TNF-α and procalcitonin after the treatment reduced 13.09 pg/mL, 5.00 pg/mL and 751.26 pg/mL, respectively compared to pre-treatment. In contrast, the levels of IL-6, TNF-α and procalcitonin increased 48.56 pg/mL, 44.48 pg/mL and 346.96 pg/mL, respectively after four days of treatment. There was a significant reduction of IL-6, TNF-α and procalcitonin in treatment group compared to the control group with p=0.022, p=0.009 and p=0.001, respectively. However, there was no significant reduction of the length of stay (p=0.072). In conclusion, administration of secretome to AECOPD patients could reduce the levels of IL-6, TNF-α and procalcitonin.
Correlation between circulating fibrosis biomarkers with left atrial function and left atrial volume index in rheumatic mitral stenosis Asrial, An A.; Reviono, Reviono; Soetrisno, Soetrisno; Setianto, Budi Y.; Widyaningsih, Vitri; Nurwati, Ida; Wasita, Brian; Pudjiastuti, Anggit
Narra J Vol. 4 No. 1 (2024): April 2024
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narra.v4i1.293

Abstract

Mitral stenosis is the most common rheumatic heart disease (RHD) disorder worldwide, including in Indonesia. This pathological condition causes left atrial pressure, leading to left atrial fibrosis that affects the structure and function of the left atrial as well as the clinical condition. The aim of this study was to assess the correlation between circulating fibrosis biomarkers with net atrioventricular compliance (Cn) as a parameter of left atrial function, and left atrial volume index (LAVI) as a parameter left atrium structure of changes. A cross-sectional study was conducted at Panti Rahayu Hospital and Permata Bunda Hospital, Purwodadi, Central Java, with a total of 40 RHD patients with severe mitral stenosis. The ELISA was used to measure the levels of carboxy-terminal propeptide of type I procollagen (PICP), matrix metalloproteinase I (MMP-1), tissue inhibitor matrix metalloproteinase 1 (TIMP-1), and transforming growth factor-β1 (TGF-β1). The left atrial function was assessed by measuring Cn, and the LAVI parameters were measured to assess left atrium structure/size. The mean levels of circulating fibrosis biomarkers were as follows: PICP 153.96±89.12 ng/mL; MMP-1 1.44±2.12 ng/mL; MMP-1/TIMP-1 ratio 0.38±0.54 and TGF-β1 2.66±1.96 pg/mL. From the echocardiographic evaluation, the mean Cn was 5.24±1.93 mL/mmHg and the mean LAVI was 152.55±79.36 mL/m2. There were significant correlation between MMP-1 and MMP-1/TIMP-1 ratio with Cn (r=0.345 and r=0.333, respectively; both had p<0.05). PICP and TGF-β1 biomarkers did not significantly correlate with Cn (p>0.05). Meanwhile, none of the biomarkers had a significant correlation with LAVI (p>0.05). This study highlights that MMP-1 and MMP-1/TIMP-1 ratio are potentially to be used as markers to determine the Cn in RHD patients with severe mitral stenosis. However, further studies with a higher sample size are needed to confirm this finding.
Impacts of Phyllanthus niruri extract on biomarker levels, macrophage count, and lesion area in an endometriotic rat model Wulandari, Eka T.; Soetrisno, Soetrisno; Purwanto, Bambang; Reviono, Reviono; Wasita, Brian; Laqif, Abdurrahman
Narra J Vol. 4 No. 3 (2024): December 2024
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narra.v4i3.1002

Abstract

Endometriosis is a gynecological disorder characterized by chronic inflammation, anatomical changes, prolonged pain, and infertility. On the other hand, Phyllanthus niruri is recognized for its pharmacological effects, which might be beneficial in managing endometriosis. The aim of the study was to investigate the pharmacological effects of P. niruri as a potential therapy for endometriosis by using an animal model. An experimental laboratory study with randomized, controlled trial, pre-test, and post-test design using 40 female Wistar rats (Rattus norvegicus) was conducted at the Integrated Research and Testing Laboratory (LPPT) of Universitas Gadjah Mada, Yogyakarta, Indonesia, from February to June 2023. Endometriosis was induced in female Wistar rats by suturing a 0.5 cm2 flap from the uterine horn to the peritoneal cavity. Changes in serum interleukin 1β (IL-1β), malondialdehyde (MDA), and matrix metalloproteinase 9 (MMP-9), before and after the treatment, were analyzed using enzyme-linked immunosorbent assay. Hematoxylin and eosin (HE) staining were used to evaluate lesion size and macrophage quantity. The results suggested that the P. niruri extract with a dose of 196 mg/200 g body weight (BW) could significantly attenuate serum IL-1β (p=0.004), MMP-9 (p=0.021), and MDA (p=0.021). Rats receiving the P. niruri extract (196 mg/200 g BW) had significantly higher macrophage counts (p=0.003), but similar lesion area (p=0.093) as compared with the negative control. In conclusion, P. niruri demonstrated promising therapeutical effects on endometriosis by modulating IL-1β, MDA, and MMP-9 levels, although the effect was not pronounced on macrophage counts and lesion area.
Co-Authors Adhiputri, Artrien Akhmad Syaikhu Alfarizi, Aditya Ana Rima Setijadi Anindita, Brigitta Devi Apriningsih, Hendrastutik Ari N Probandari Ari Natalia Probandari Asrial, An A. Atmojo, Anang Purwoko Bambang Purwanto Bhisma Murti Brian Wasita Damayanti, Raninditya Dhani Redhono, Dhani Endang Sutisna Endang Sutisna Sulaeman Fahlevie, Fahlevie Hapsari, Brigitta Anindita Devi Hapsari, Brigitta DA. Hapsari, Brigitta Devi Anindita Harsini Harsini Hermansah, Muhamad Lukman Hermawati, Berty Denny Ida Nurwati Irwandi, Delvan Jatu Aphridasari Kartodarsono, Supriyanto Laqif, Abdurrahman Leli Saptawati Lestari, Anggraini Dwi Lilik Lestari marwoto marwoto Mochammad Imron Awalludin Murti, Paulus Wisnu Kuncoro Myrtha, Risalina Nur Hafidha Hikmayani Prabowo, Nurhasan Agung Pudjiastuti, Anggit Putranto, Wachid Putri, Desy Puspa Putro, Prasetyo Sarwono R, Sari Apriliana Raharjo, A Farih Rahayu, Nur Indah Ramadhiana, Yusniar Roxanne, Olivia Geraldine Sebayang, Pribadi M Septiawan, Debree Setianingsih, Wahyu Setianto, Budi Y. Setyowati, Arry Soetejo, FX Soetrisno Soetrisno Soewondo, Widiastuti Subandrio, Subandrio SURYAWATI, BETTY Sutanto, Yusup S. Vagheggini, Guido Vitri Widyaningsih Wati, Martha Ratna Widyasanti, Diana Windu Prasetyo, Windu Wulandari, Eka T. Yudhi Prasetyo, Yudhi Yundari, Yundari Yusup Subagio Sutanto